Clinical Trial Update: A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide [Phase 3]

View source ↗

Summary

This Phase 3 study is evaluating a combination of Tobevibart and Elebsiran in participants with chronic hepatitis D infection not virologically suppressed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis D

Drugs mentioned

• Elebsiran
• Tobevibart

Snippet

Sponsor: Vir Biotechnology, Inc. | Conditions: Viral Hepatitis | Phase 3 | Status: RECRUITING